<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Michel Goedert</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Cambridge<br>MRC Laboratory of Molecular Biology</td>
</tr>
<tr>
<td class="label">Country</td>
<td>UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>250</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-5857-7687" target="_blank">0000-0002-5857-7687</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [FTD](/diseases/ftd)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Tau](/mechanisms/tau-pathology), [Alpha-synuclein](/mechanisms/alpha-synuclein), [Protein aggregation](/mechanisms/protein-aggregation)</td>
</tr>
</table>
Michel Goedert
Overview
Michel Goedert is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Cambridge and MRC Laboratory of Molecular Biology. Their research focuses on Tau, Alpha-synuclein, Protein aggregation, with particular emphasis on Alzheimer's Disease and Parkinson's Disease and FTD. With an h-index of 250, Goedert is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Michel Goedert</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Cambridge<br>MRC Laboratory of Molecular Biology</td>
</tr>
<tr>
<td class="label">Country</td>
<td>UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>250</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-5857-7687" target="_blank">0000-0002-5857-7687</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [FTD](/diseases/ftd)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Tau](/mechanisms/tau-pathology), [Alpha-synuclein](/mechanisms/alpha-synuclein), [Protein aggregation](/mechanisms/protein-aggregation)</td>
</tr>
</table>
Michel Goedert
Overview
Michel Goedert is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Cambridge and MRC Laboratory of Molecular Biology. Their research focuses on Tau, Alpha-synuclein, Protein aggregation, with particular emphasis on Alzheimer's Disease and Parkinson's Disease and FTD. With an h-index of 250, Goedert is among the most cited researchers in the neuroscience field[@orcid2026].
Goedert's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Parkinson's Disease and FTD. Their research group has made significant contributions to the fields of Tau, Alpha-synuclein, Protein aggregation, publishing in high-impact journals including Nat Neurosci, Brain.
Based at University of Cambridge and MRC Laboratory of Molecular Biology, Goedert collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [FTD](/diseases/ftd)
Mechanisms of Interest
- [Tau](/mechanisms/tau-pathology)
- [Alpha-synuclein](/mechanisms/alpha-synuclein)
- [Protein aggregation](/mechanisms/protein-aggregation)
Programmatic Emphasis
Goedert's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease and Parkinson's Disease and FTD[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Tau, Alpha-synuclein, Protein aggregation domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[Tau pathology in Alzheimer's disease](https://doi.org/10.1038/nn.4018). Nat Neurosci, 2015.[@tau2015]
[Alpha-synuclein in Lewy body disease](https://doi.org/10.1093/brain/124.8.1433). Brain, 2001.[@alphasynuclein2001]
Recent Research
Recent PubMed-indexed publications (2025-present):
[Seeding biosensor cell line that reproduces the Alzheimer tau fold.](https://pubmed.ncbi.nlm.nih.gov/41260337/). The Journal of biological chemistry. 2025.
[Author Correction: Structures of α-synuclein filaments from multiple system atrophy.](https://pubmed.ncbi.nlm.nih.gov/41125897/). Nature. 2025.
[Distinct tau filament folds in human MAPT mutants P301L and P301T.](https://pubmed.ncbi.nlm.nih.gov/40442318/). Nature structural & molecular biology. 2025.
[Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.](https://pubmed.ncbi.nlm.nih.gov/40044789/). Nature structural & molecular biology. 2025.
Collaborators and Research Network
[John Hardy](/researchers/john-hardy), [Virginia M.-Y. Lee](/researchers/virginia-lee), [John Q. Trojanowski](/researchers/john-trojanowski)
Institutional Context
Primary institutional links: [University of Cambridge](/institutions/university-of-cambridge), [MRC Laboratory of Molecular Biology](/institutions/mrc-laboratory-of-molecular-biology). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Tau, Alpha-synuclein, Protein aggregation signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Parkinson's Disease and FTD into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0002-5857-7687](https://orcid.org/0000-0002-5857-7687)
- Google Scholar: [Search for Michel Goedert](https://scholar.google.com/scholar?q=author%3A%22Michel+Goedert%22)
- PubMed: [Author search for Michel Goedert](https://pubmed.ncbi.nlm.nih.gov/?term=Michel+Goedert%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, Tau pathology in Alzheimer's disease (2015)](https://doi.org/10.1038/nn.4018)
[Unknown, Alpha-synuclein in Lewy body disease (2001)](https://doi.org/10.1093/brain/124.8.1433)
Unknown, ORCID profile for Michel Goedert (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)